Lindbrook Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Lindbrook Capital’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-22	Closed	-$246	–	2730
2023 Q3	$246	Sell	22 -69	-76%	-$1.11K	﹤0.01%	2620
2023 Q2	$1.95K	Buy	91 +80	+727%	+$2.36K	﹤0.01%	2158
2023 Q1	$445	Sell	11 -28	-72%	-$1.34K	﹤0.01%	2626
2022 Q4	$1.81K	Buy	39 +26	+200%	+$1.19K	﹤0.01%	2274
2022 Q3	$1K	Hold	13	–	–	﹤0.01%	2305
2022 Q2	$1K	Sell	13 -73	-85%	-$3.96K	﹤0.01%	2216
2022 Q1	$6K	Buy	86 +73	+562%	+$4.75K	﹤0.01%	1514
2021 Q4	$1K	Hold	13	–	–	﹤0.01%	1905
2021 Q3	$1K	Hold	13	–	–	﹤0.01%	1700
2021 Q2	$1K	Hold	13	–	–	﹤0.01%	1744
2021 Q1	$1K	Hold	13	–	–	﹤0.01%	1702
2020 Q4	$1K	Sell	13 -11	-46%	-$484	﹤0.01%	1602
2020 Q3	$1K	Sell	24 -29	-55%	-$1.41K	﹤0.01%	1539
2020 Q2	$3K	Buy	53 +20	+61%	+$1.03K	﹤0.01%	1246
2020 Q1	$2K	Buy	+33	New	+$1.76K	﹤0.01%	1280

Other funds holding ENTA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Lindbrook Capital's ENTA Position: Q4 2023 in Review

Lindbrook Capital sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 22 shares — an estimated $246 sold.

Lindbrook Capital first reported a position in ENTA in Q1 2020 and held it in 15 quarters. The position peaked at $6K in Q1 2022. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

Lindbrook Capital reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Lindbrook Capital sold 22 Enanta Pharmaceuticals shares in Q4 2023, an estimated $246.
Lindbrook Capital first reported a position in Enanta Pharmaceuticals in Q1 2020 and held it in 15 quarters.
Lindbrook Capital's Enanta Pharmaceuticals position peaked at $6K in Q1 2022.
105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Lindbrook Capital's 13F filing for Q4 2023, filed 1 Feb 2024.